Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia

Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-...

Celý popis

Podrobná bibliografia

Vydané v:	Retina (Philadelphia, Pa.) Ročník 29; číslo 8; s. 1062
Hlavný autor:	Cohen, Salomon Y
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.09.2009
Predmet:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Humans Myopia, Degenerative - complications Myopia, Degenerative - drug therapy Ranibizumab Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects
ISSN:	1539-2864, 1539-2864
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!